非対称性ダイメチルアルギニンの合成受容体
Lindsey I James1, Joshua E Beaver, Natalie W Rice
1Department of Chemistry, CB 3290, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Journal of the American Chemical Society
|April 9, 2013
まとめ
研究者らは,アシンメトリック・ジメチル・アルギニン (aRMe2) を検出するための新しい小分子受容体A2Dを開発し,これは様々な疾患に関連したタンパク質の改変である. この発見は,これらの状態を標的とした新しい診断および治療戦略の可能性を秘めています.
科学分野:
- 化学生物学 化学生物学とは
- 分子生物学は分子生物学である.
- バイオケミストリー バイオケミストリー
背景:
- 非対称性ダイメチルアルギニン (aRMe2) は,癌や神経退行性疾患などの様々な疾患に関与する重要なタンパク質の翻訳後の改変 (PTM) である.
- aRMe2認識の分子メカニズムを理解することは,標的治療の開発に不可欠です.
研究 の 目的:
- 非対称性ダイメチルアルギニン (aRMe2) と選択的に結合できる新しい小分子受容体を特定し,特徴づけること.
- aRMe2.と特定された受容体の結合親和性,選択性,相互作用モードを調査する.
主な方法:
- 動的結合化学を用いて,小分子受容体A2D.を発見した.
- 結合親和性と選択性は,ジメチルアルギニンの同位体形態に対して評価されました.
- 結合相互作用を明らかにするために,受容体-PTM複合体の構造的特徴づけが行われました.
主要な成果:
- 小分子受容体A2Dという新しい小分子受容体が,非対称性ダイメチルアルギニン (aRMe2) について特定されました.
- A2Dは,微小分子結合親和度が低く,対称的なディメチルアルギニンよりもaRMe2に対する2.5-7.5倍の選択性を示した.
- カチオン-π相互作用は,A2D-aRMe2結合の主要な原動力として特定され,自然なタンパク質認識を模倣した.
結論:
- 新型小分子受容体A2Dは,aRMe2.0に対する選択的化学探査装置を提供している.
- この発見は,治療上の利益のためにaRMe2-タンパク質の相互作用を調節する小分子を設計するための基礎を提供します.
- この研究は,合成受容体によるPTM認識の理解を前進させる.
関連する概念動画
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:31Internal Receptors
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
01:00Enzyme-linked Receptors
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...